RARA CRAFT DATABASE for FDA Medical Devices
PMAP210003

FDA DEVICE FACTS

ARCHITECT HBsAg Next Qualitative Reagent Kit, ARCHITECT HBsAg Next Confirmatory Reagent Kit, ARCHITECT HBsAg NEXT Qualit

Abbott Laboratories

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEAugust 10, 2022PRODUCT CODELOM

Indications for use

ARCHITECT HBsAg NEXT Qualitative Reagent Kit The HBsAg Next Qualitative assay is a chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of Hepatitis B surface antigen (HBsAg) in human adult and pediatric (2 years to 21 years of age) serum, serum separator tube, and plasma (dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin separator, sodium heparin) on the ARCHITECT i System. The assay may also be used to screen for hepatitis B virus (HBV) infection in pregnant women to identify neonates who are at risk for acquiring hepatitis B during the perinatal period. Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with HBV (state of infection or associated disease not determined) in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis B infection. WARNING: Not approved for use in screening blood, plasma, tissue donors, or cadaveric specimens.

ARCHITECT HBsAg NEXT Confirmatory Reagent Kit The HBsAg Next Confirmatory assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative confirmation of the presence of hepatitis B surface antigen (HBsAg) in human adult and pediatric (2 years to 21 years of age) serum, serum separator, and plasma (dipotassium EDTA, tripotassium EDTA, lithium heparin, lithium heparin separator, sodium heparin) by means of specific antibody neutralization on the ARCHITECT i System Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with the hepatitis B virus (HBV) (state of infection or associated disease not determined) in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis B infection. It is intended to be used for the confirmation of samples found to be repeatedly reactive by HBsAg Next Qualitative. It is intended to be used for the confirmation of samples found to be repeatedly reactive by HBsAg Next Qualitative. WARNING: Not approved for use in screening blood, plasma, tissue donors, or cadaveric specimens. The effectiveness of the ARCHITECT HBsAg Next Confirmatory assay for use in screening blood, plasma, or tissue donors has not been established. ARCHITECT HBsAg NEXT Qualitative Calibrators The HBsAg Next Qualitative Calibrators are for the calibration of the ARCHITECT i System when used for qualitative determination and confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma. ARCHITECT HBsAg NEXT Qualitative Controls The HBsAg Next Qualitative Controls are for the estimation of test precision and the detection of systematic analytical deviations of the ARCHITECT i System when used for the qualitative detection and for the confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma. ARCHITECT HBsAg NEXT Confirmatory Manual Diluent The HBsAg Next Confirmatory Manual Diluent is used for manually diluting specimens for testing on the ARCHITECT i System.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026